文献速递心胸血管麻醉术前评估与围术期医学

右美托咪定对主动脉手术后急性肾损伤的影响:单中心安慰剂对照随机试验

Effect of dexmedetomidine on acute kidney injury after aortic surgery: a single-centre, placebo-controlled, randomised controlled trial.
PubMed 文献 · Br J Anaesth · 2020-01-29

该单中心安慰剂对照随机试验纳入108例需体外循环的主动脉手术患者,麻醉诱导后以0.4 μg kg-1 h-1输注右美托咪定或生理盐水24小时。右美托咪定组AKI发生率为13%(7/54),低于生理盐水组的31%(17/54),OR=0.32(95%CI 0.12-0.86;P=0.026),且不增加心动过缓或低血压风险,住院时间更短。

要点

  • 麻醉诱导后24小时输注右美托咪定0.4 μg kg-1 h-1可降低主动脉手术后AKI发生率。
  • 右美托咪定组AKI 13% vs 生理盐水组31%,OR=0.32(95%CI 0.12-0.86;P=0.026)。
  • 心动过缓、低血压及卒中、死亡、谵妄等次要结局组间无显著差异。

核心结论

  • 麻醉诱导后开始24小时预防性输注右美托咪定可减少需体外循环的主动脉手术后急性肾损伤发生率。
  • 未观察到与右美托咪定镇静或交感抑制作用相关的不良副作用。

研究设计与样本

  • 单中心、安慰剂对照、随机对照试验,共纳入108例需体外循环的主动脉手术患者。
  • 患者随机接受右美托咪定或生理盐水,速率0.4 μg kg-1 h-1,麻醉诱导后开始持续24小时。
  • 主要结局为按KDIGO标准定义的急性肾损伤发生率。

主要发现

  • 右美托咪定组AKI发生7/54(13%),生理盐水组17/54(31%),OR=0.32(95%CI 0.12-0.86;P=0.026)。
  • 卒中、死亡和谵妄等次要结局在右美托咪定组(16/54,30%)与生理盐水组(22/54,41%)之间相似,OR=0.61(95%CI 0.28-1.36)。
  • 心动过缓发生率右美托咪定组14/54(26%)vs 生理盐水组17/54(32%),OR=0.76(95%CI 0.33-1.76)。
  • 低血压发生率右美托咪定组29/54(54%)vs 生理盐水组36/54(67%),OR=0.58(95%CI 0.27-1.26)。
  • 住院时间右美托咪定组12(10-17)天,短于生理盐水组的15(11-21)天(P=0.039)。

关键数值与推荐

  • AKI定义采用KDIGO标准。
  • 右美托咪定输注速率0.4 μg kg-1 h-1,麻醉诱导后开始持续24小时。
  • 主要结局AKI发生率组间比较OR=0.32(95%CI 0.12-0.86;P=0.026)。

临床怎么用

  • 对需体外循环的主动脉手术患者,可考虑麻醉诱导后以0.4 μg kg-1 h-1输注右美托咪定24小时以降低AKI风险。
  • 该方案未增加心动过缓或低血压发生率,但需按常规监测血流动力学。

局限性

  • 单中心研究,样本量108例,结论外推需谨慎。
  • 次要结局包括卒中、死亡和谵妄的组间比较未报告统计学显著性差异,置信区间较宽。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute kidney injury (AKI) is a frequent and serious complication after aortic surgery requiring cardiopulmonary bypass (CPB). Dexmedetomidine, a selective α-2 adrenoreceptor agonist, may reduce AKI because of its sympatholytic and anti-inflammatory effects against ischaemia-reperfusion injury. We investigated the effect of dexmedetomidine administration on AKI after aortic surgery requiring CPB in a placebo-controlled randomised controlled trial. METHODS: A total of 108 patients were randomly assigned to an infusion of dexmedetomidine or saline at a rate of 0.4 μg kg-1 h-1 for 24 h starting after anaesthetic induction. The primary outcome was the incidence of AKI, as defined by the Kidney Disease: Improving Global Outcomes (KDIGO) criteria. The secondary outcomes included delirium and major morbidity. Safety outcomes were drug-related adverse events (bradycardia, hypotension). RESULTS: AKI occurred in 7/54 (13%) subjects randomised to dexmedetomidine, compared with 17/54 (31%) subjects randomised to saline infusion (odds ratio=0.32; 95% confidence interval [CI], 0.12-0.86; P=0.026). Secondary outcomes, including stroke, mortality, and delirium, were similar between subjects randomised to dexmedetomidine (16/54 [30%] or saline control (22 [41%]; odds ratio=0.61 [95% CI, 0.28-1.36]). The incidence of bradycardia and hypotension was similar between groups (14/54 (26%) vs. 17/54 (32%) (odds ratio:0.76 (95%CI:0.33-1.76) and 29/54 (54%) vs. 36/54 (67%) (odds ratio:0.58 (95%CI:0.27-1.26), respectively). The length of hospital stay was shorter in the dexmedetomidine group (12 [10-17] days) vs saline control (15 [11-21] days; P=0.039). CONCLUSIONS: Pre-emptive dexmedetomidine administration for 24 h starting after induction of anaesthesia reduced the incidence of AKI after aortic surgery requiring CPB, without any untoward side-effects related to its sedative or sympatholytic effects. CLINICAL TRIAL REGISTRATION: NCT02607163 (www. CLINICALTRIALS: gov).

来源:Br J Anaesth,查看原文。版权归原作者所有。

引用

  1. Soh S, Shim JK, Song JW, et al. Effect of dexmedetomidine on acute kidney injury after aortic surgery: a single-centre, placebo-controlled, randomised controlled trial. Br J Anaesth. 2020. PMID: 32007239. doi:10.1016/j.bja.2019.12.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。